The determinants of tumour immunogenicity

Nature Reviews Cancer

Volumn 12, Issue 4, 2012, Pages 307-313

  Blankenstein, Thomas ^a,b   Coulie, Pierre G ^c   Gilboa, Eli ^d   Jaffee, Elizabeth M ^e  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c DE DUVE INSTITUTE   (Belgium)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; NATURAL KILLER CELL RECEPTOR; REACTIVE OXYGEN METABOLITE; SIPULEUCEL T; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ANTIGENICITY; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; COLORECTAL CARCINOMA; COMPETITIVE INHIBITION; DOWN REGULATION; EMBRYO DEVELOPMENT; EXTRACELLULAR MATRIX; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MISMATCH REPAIR; MOLECULAR DYNAMICS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM PROCESSES; IMMUNOMODULATION; MICE; NEOPLASMS; TUMOR ESCAPE;

EID: 84858797296     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3246     Document Type: Review

References (68)

1. Willimsky, G. et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 205, 1687-1700 (2008). (Pubitemid 351962031)
2. Seung, L. P., Seung, S. K. & Schreiber, H. Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res. 55, 5094-5100 (1995).
3. Preiss, S., Kammertoens, T., Lampert, C., Willimsky, G. & Blankenstein, T. Tumor-induced antibodies resemble the response to tissue damage. Int. J. Cancer 115, 456-462 (2005). (Pubitemid 40663751)
4. Lennerz V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013-16018 (2005). (Pubitemid 41552859)
5. Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994). (Pubitemid 24140418)
6. van der Bruggen, P. et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647 (1991). (Pubitemid 21917508)
7. Gotter, J., Brors, B., Hergenhahn, M. & Kyewski, B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004). (Pubitemid 38139246)
8. Kloor, M., Michel, S. & von Knebel Doeberitz, M. Immune evasion of microsatellite unstable colorectal cancers. Int. J. Cancer 127, 1001-1010 (2010).
9. Casares, N. et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202, 1691-1701 (2005). (Pubitemid 41815875)
10. Fridman, W. H. et al. Prognostic and predictive impact of intra-and peritumoral immune infiltrates. Cancer Res. 71, 5601-5605 (2011).
11. Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358, 2698-2703 (2008). (Pubitemid 351860862)
12. Perez-Diez, A. et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109, 5346-5354 (2007). (Pubitemid 46890556)
13. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev. Immunol. 6, 715-727 (2006). (Pubitemid 44453458)
14. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J. & Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol. 3, 991-998 (2002). (Pubitemid 35363648)
15. Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214-224 (2006). (Pubitemid 43882974)
16. Tredan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441-1454 (2007).
17. Hamzah, J. et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453, 410-414 (2008). (Pubitemid 351693122)
18. Buckanovich, R. J. et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Med. 14, 28-36 (2008).
19. Burnet, F. M. Immunological factors in the process of carcino-genesis. Br. Med. Bull. 20L, 154-158 (1964).
20. Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329-333 (1982). (Pubitemid 13119667)
21. Langman, R. E., Cohn, M. A minimal model for the self-non-self discrimination: a return to the basics. Semin. Immunol. 12, 189-195 (2000). (Pubitemid 30479438)
22. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of Cancer Immunosurveillance and Immunoediting. Immunity 21, 137-148 (2004). (Pubitemid 39094044)
23. Pradeu, T. & Carosella, E. D. On the definition of a criterion of immunogenicity. Proc. Natl Acad. Sci. USA 103, 17858-17861 (2006). (Pubitemid 44852250)
24. Drake, C. G., Jaffee, E. M. & Pardoll, D. M. Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51-81 (2006). (Pubitemid 43765799)
25. Laheru, D. A. & Jaffee, E. M. Immunotherapy for pancreatic cancer-science driving clinical practice. Nature Rev. Cancer 5, 459-467 (2005). (Pubitemid 40791488)
26. Cohn, M. The immune system: a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs. Immunol. Rev. 185, 24-38 (1992).
27. Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of "tumor escape" variants. Nature Immunol. 3, 999-1005 (2002). (Pubitemid 35363649)
28. Klein, G. & Klein, E. Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc. Natl Acad. Sci. USA 74, 2121-2125 (1977). (Pubitemid 8123623)
29. Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001). (Pubitemid 32391043)
30. Qin, Z. & Blankenstein, T. A cancer immunosurveillance controversy. Nature Immunol. 5, 3-4 (2004).
31. Kammertoens, T., Qin, Z., Briesemeister, D., Bendelac, A. & Blankenstein, T. Methylcholanthrene-induced carcinogenesis is promoted by B-cells and IL-4 but there is no evidence for a role of T/NKT-cells and their effector molecules (Fas-ligand, TNF-α, perforin). Int. J. Cancer 31 Jan 2012 (doi:10.1002/ijc.27411).
32. Pantel, K. & Uhr, J. W. Controversies in clinical cancer dormancy. Proc. Natl Acad. Sci. USA 108, 12396-12400 (2011).
33. Garrido, F., Cabrera, T. & Aptsiauri, N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 127, 249-256 (2010).
34. Gajewski, T. F. et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006). (Pubitemid 44401498)
35. Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Med. 9, 1269-1274 (2003). (Pubitemid 37279849)
36. Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197-203 (2011).
37. Pilotte, L. et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl Acad. Sci. USA 109, 2497-2502 (2012).
38. Demotte, N. et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res. 70, 7476-7488 (2010).
39. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Med. 10, 942-949 (2004). (Pubitemid 39273735)
40. Gobert, M. et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69, 2000-2009 (2009).
41. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
42. Boon, T., Coulie, P. G., Van den Eynde, B. & van der Bruggen, P. Human T cell responses against melanoma. Annu. Rev. Immunol. 24, 175-208 (2006).
43. Corbière, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253-1262 (2011).
44. Willimsky, G. & Blankenstein, T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437, 141-146 (2005). (Pubitemid 41613441)
45. Neefjes, J., Jongsma, M. L., Paul, P. & Bakke, O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Rev. Immunol. 11, 823-836 (2011).
46. Rezvani, K. & de lavallade, H. Vaccination strategies for lymphomas and leukemias: recent progress. Drugs 71, 1659-1674 (2011).
47. Scanlan, M. J., Gure, A. O., Jungbluth, A. A., Old, L. J. & Chen, Y. T. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002). (Pubitemid 35398862)
48. Zheng, L. et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PLoS ONE 6, e19390 (2011).
49. Lampen, M. H. & van Hall, T. Strategies to counteract MHC-1 defects in tumors. Curr. Opin. Immunol. 23, 293-298 (2011).
50. Topalian, S. L., Weiner, G. J. & Pardoll, D. M. Cancer immunotherapy comes of age. J. Clin. Oncol. 29, 4828-4836 (2011).
51. Schietinger, A., Delrow, J. J., Basom, R. S., Blattman, J. N. & Greenberg, P. D. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335, 723-727 (2012).
52. Ganss, R. & Hanahan, D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58, 4673-4681 (1998). (Pubitemid 28480634)
53. Huber, M. L., Haynes, L., Parker, C. & Iversen, P. Interdisciplinary critique of Sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104, 1-7 (2012).
54. Horowitz, M. M. et al. Graft-versus-Leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990). (Pubitemid 20069191)
55. Wilde, S. et al. Dendritic cells pulsed with RNA encoding allogenic MHC and antigen induce T cells with superior anti-tumor activity and higher functional TCR avidity. Blood 114, 2131-2139 (2009).
56. Li, L.-P. et al. Transgenic mice with a diverse human T-cell antigen receptor repertoire. Nature Med. 16, 1029-1034 (2010).
57. Schumacher, T. N. T-cell-receptor gene therapy. Natur. Rev. Immunol. 2, 512-519 (2002). (Pubitemid 37328742)
58. Offringa, R. Antigen choice in adoptive T-cell therapy of cancer. Curr. Opin. Immunol. 21, 190-199 (2009).
59. Nair, S. et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102, 964-971 (2003). (Pubitemid 36917791)
60. Niethammer, A. G. et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med. 8, 1369-1375 (2002). (Pubitemid 36019421)
61. Pastor, F., Kolonias, D., Giangrande, P. H. & Gilboa, E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465, 227-230 (2010).
62. Pastor, F., Kolonias, D., McNamara, J. O. & Gilboa, E. Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol. Ther. 19, 1878-1886 (2011).
63. Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Med. 15, 808-813 (2009).
64. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
65. Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031-1035 (2010).
66. Ma, Y. et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Sem. Immunol. 22, 113-124 (2010).
67. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
68. Hodi, F. S. et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).